Altana Pharma Extends Collaboration With Atugen Another Year

Feb 17, 2005

NEW YORK, Feb. 17 (GenomeWeb News) - Atugen has extended by one year its non-exclusive target validation and license agreement with Altana Pharma, the company said yesterday.

The extended deal, originally signed in 2001, calls for Atugen to continue validating potential targets supplied by Altana. The agreement provides a license to Altana's gene-silencing and oligonucleotide-delivery technologies.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Faster Profiles

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

Standards Needed

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

Conflict Search

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

This Week in Science

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.

Main menu